Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating birtamimab in Mayo Stage IV AL amyloidosis was terminated, but results have been posted on 2025-12-16.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• Birtamimab (birtamimab)

Snippet

Sponsor: Prothena Biosciences Ltd. | Conditions: Light Chain (AL) Amyloidosis | Phase 3 | Status: TERMINATED | Results posted: 2025-12-16